Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Dose-Escalation and Safety Run-in Phase Ib Study

Nilanjan Ghosh,William Townsend,Michael Dickinson,Max Topp,Monica Tani,Armando Santoro,Michael Crump,Franck Morschhauser,Steven Le Gouill,Amitkumar Mehta,Anesh Panchal,Chun Wu,Martin Barrett,Kathryn Humphrey,Naseer Qayum,Martin Hutchings

doi:10.1182/blood-2021-147780

Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Dose-Escalation and Safety Run-in Phase Ib Study

Nilanjan Ghosh, William Townsend + Show 14 more

Open Access

https://doi.org/10.1182/blood-2021-147780

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2021
Citations: 7

Affiliation: Royal Melbourne Hospital, Levine Cancer Institute, University Hospital Würzburg, Princess Margaret Cancer Centre, Roche (United Kingdom), Ospedale "Santa Maria delle Croci" di Ravenna, Rigshospitalet, University of Lille, Centre Hospitalier Universitaire de Lille, University College London, IRCCS Humanitas Research Hospital, University of Alabama at Birmingham, Centre Hospitalier Universitaire de Nantes

#Speakers Bureau #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Dose-Escalation and Safety Run-in Phase Ib Study

Full Text